Work

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.776

Authors: Sandip M Prasad, Dimitar Shishkov, Nikola V Mihaylov, Alexandre Khuskivadze, Pencho Genov, Vasyl Terzi, Max Kates, William C. Huang, Michael J Louie, Sunil Raju, Brent Burger, Andrew Meads, Mark Schoenberg, ENVISION Study Group

Institutions: Morristown Medical Center, Atlantic Health System, University Multipurpose Hospital for Active Treatment "Sveti Georgi", National Institute of Emergency Medicine "Pirogov", Johns Hopkins University, Johns Hopkins Hospital, NYU Langone Health, UroGen Pharma Ltd. (United States), Albert Einstein College of Medicine

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: UroGen Pharma

OpenAlex ID: W4407702132

Cites:

Cited by:

Related to: 10